Proteasome inhibitors in cancer therapy: Treatment regimen and peripheral neuropathy as a side effect

详细信息    查看全文

• 作者：Gulce Sari Kaplan^a ; Ceyda Corek Torcun^a ; Tilman Grune^b ; Nesrin Kartal Ozer^a ; Betul Karademir^a ; ^{betulkarademir@marmara.edu.tr}
• 关键词：AIF ; apoptosis inducing factor ; Ang ; angiopoietin ; AP-1 ; activator protein-1 ; APEX ; Assessment of Proteasome Inhibition for Extending Remissions ; ATP ; adenosine-5&prime ; -triphosphate ; BiPN ; bortezomib-induced peripheral neuropathy ; CiPN ; chemotherapy-induced peripheral neuropathy ; CREST ; Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma ; DRG ; dorsal root ganglia ; FDA ; food and drug administration ; IL ; interleukin ; MDM2 ; mouse double minute 2 ; MDR1
• 刊名：Free Radical Biology and Medicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：103
• 期：Complete
• 页码：1-13
• 全文大小：1084 K
• 卷排序：103

文摘

Proteasomal system is involved in the regulation of many cancer related pathways. Targeting proteasome in cancer cells increases the efficiency of cancer therapy. Bortezomib is a first-in-class proteasome inhibitor with FDA approval. Peripheral neuropathy is a dose-limiting toxic side effect of bortezomib. The second-generation proteasome inhibitor carfilzomib is less neurotoxic.